CHICAGO – With a $16 million National Cancer Institute grant in hand, the Broad Institute, the Dana-Farber Cancer Institute, and nonprofit cancer research organization Count Me In are developing workflows to involve patients with rare mutations more directly in studies about their diseases.
The centerpiece of this new initiative is a plan to return patient-specific results of germline and somatic sequencing in two rare cancers, osteosarcoma and leiomyosarcoma.